Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.52 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909783 | 1.00 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL6304719 | 0.90 | HTR2C (0.50) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL8263142 | 0.86 | CD44 (0.41) | PNMTHTR2AHTR2CHTR2B | |
| SCHEMBL184089 | 0.86 | PNMT (0.61) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL4575618 | 0.86 | PNMT (0.50) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3882867 | 0.84 | CD44 (0.39) | PNMTHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL184033 | 0.84 | PNMT (0.59) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL20909790 | 0.77 | PNMT (0.47) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL22545196 | 0.77 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL21475687 | 0.77 | ADCY6 (0.57) | PNMTASIC3ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| WO-2020210380-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PNMT 3528/4885ASIC3 4614/4885HTR2A 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.